Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.
Erik Bengtsen, MD, explained how antidepressants may improve quality of life and how he typically works with patients who ...
As radiotherapy becomes more strategically integrated around CAR T-cell therapy in multiple myeloma, clinicians face a choice ...
In a phase 1 trial of patients with platinum-sensitive high-grade ovarian cancer, a personalized neoantigen vaccine plus ...
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose ...
The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and ...
Ralph V. Boccia, MD, FACP, compared MRD data with Tec-Dara and Tal-Dara and explained how sustained MRD negativity is reshaping myeloma care.
Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after ...
Data from the phase 2/3 QUILT-3.032 trial support the expanded indication for nogapendekin alfa in BCG-unresponsive ...
The FDA has accepted a resubmitted biologics license application (BLA) for tabelecleucel (tab-cel; Ebvallo), with a proposed ...
Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results